References
1. Williamson DR, Albert M, Heels-Ansdell D, et al. Thrombocytopenia in
critically ill patients receiving thromboprophylaxis: frequency, risk
factors, and outcomes. Chest 2013;44:1207-1215.
2. Song JC, Liu SY, Zhu F, et al. Expert consensus on the diagnosis and
treatment of thrombocytopenia in adult critical care pa-tients in China.
Mil Med Res 2020;45:457-474.
3. Neunert C, Terrell DR, Arnold DM, et al. American Society of
Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv
2019;3:3829-3866.
4. Williamson DR, Lesur O, Tétrault JP, et al. Thrombocytopenia in the
critically ill: prevalence, incidence, risk factors, and clinical
outcomes. Can J Anaesth 2013;60:641-651.
5. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis,
evaluation, and management. Hematology Am Soc Hematol Educ Program
2009;153-158.
6. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia
and prognosis in intensive care. Crit Care Med 2000;28:1871-1876.
7. Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of
laboratory testing for drug-induced immune thrombo-cytopenia. J Thromb
Haemost 2013;11:169-176.
8. He N, Su S, Zhai SD, et al. Evidence-based guideline for therapeutic
drug monitoring of Vancomycin: 2020 update. Chin Med J 2021;19:12-16.
9. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical
criteria for sepsis: for the third International Consensus Def-initions
for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762-74.
10. Berger MM, Marazzi A, Freeman J, et al. Evaluation of the
consistency of Acute Physiology and Chronic Health Evaluation (APACHE
II) scoring in a surgical intensive care unit. Crit Care Med
1992;20:1681-7.
11. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over
time in ICU patients: reliability and validity of the Richmond
Agitation-Sedation Scale (RASS). JAMA 2003;289:2983–2991.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the
probability of adverse drug reactions. Clin Pharmacol Ther
1981;30:239-245.
13. Zhou D, Shi T, Zhao S, et al. Linezolid is safe on platelet count
for AML patients during myelosuppression after consolida-tion
chemotherapy. J Clin Pharm Ther 2020;45(4):755-758.
14. Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of
long-term linezolid and vancomycin therapy in a pro-spective
observational study of patients with orthopedic infections. Clin Infect
Dis 2004;38(8):1058-1064.
15. Nasraway SA, Shorr AF, Kuter DJ, et al Linezolid does not increase
the risk of thrombocytopenia in patients with nosocomi-al pneumonia:
comparative analysis of linezolid and vancomycin use. Clin Infect Dis
2003;37(12):1609-1616.
16. Patel N, VanDeWall H, Tristani L, et al. A comparative evaluation of
adverse platelet outcomes among Veterans’ Affairs patients receiving
linezolid or vancomycin. J Antimicrob Chemother 2012;67(3):727-735.
17. Fujii S, Takahashi S, Makino S, et al. Impact of vancomycin or
linezolid therapy on development of renal dysfunction and
thrombocytopenia in Japanese patients. Chemotherapy 2013;59(5):319-324.
18. Marinho DS, Huf G, Ferreira BL, et al. The study of vancomycin use
and its adverse reactions associated to patients of a Brazilian
university hospital. BMC Res Notes 2011;4:236.
19. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale
(NOS) for assessing the quality of non-randomised studies in
meta-analyses. 2013.
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
20. Joanna Briggs Institute. Checklist for analytical cross sectional
studies. https://jbi.global/critical-appraisal-tools
21. Walker RW, Heaton A. Thrombocytopenia due to vancomycin. Lancet
1985;1:932.
22. Howard CE, Adams LA, Admire JL, et al. Vancomycin-induced
thrombocytopenia: a challenge and rechallenge. Ann Phar-macother
1997;31:315-318.
23. Reese JA, Nguyen LP, Buchanan GR, et al. Drug-induced
thrombocytopenia in children. Pediatr Blood Cancer 2013;60:1975-1981.
24. Mohammadi M, Jahangard-Rafsanjani Z, Sarayani A, et al.
Vancomycin-induced thrombocytopenia: A Narrative Review. Drug Saf
2017;40:49-59.
25. Wang JX, Zhang FC, Liu XQ, et al. Expert consensus for diagnosis and
treatment of thrombocytopenia in China. Chin J Intern Med
2020;59:498-510.
26. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced
immune thrombocytopenia. N Engl J Med 2007;356:904-910.
27. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign:
International Guidelines for Management of Sepsis and Septic Shock:
2016. Intensive Care Med 2017;43:304-377.
28. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of
linezolid: summary of clinical experience. Antimicrob Agents Chemother
2002;46:2723-2726.
29. Leach M F, Cooper L K, Aubuchon J P. Detection of drug-dependent,
platelet-reactive antibodies by solid-phase red cell ad-herence assays.
Br J Haematol 1997;97:755-761.
Table
1 Body temperature, blood routine examinations and procalcitonin
(D1-D9) †